Sichuan Hebang Biotechnology Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Xiaoping Zeng

İcra Kurulu Başkanı

CN¥2.6m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Xiaoping Zeng (63 yo)

1.5yrs

Görev süresi

CN¥2,619,400

Tazminat

Mr. Xiaoping Zeng is Chairman & GM of Sichuan Hebang Biotechnology Corporation Limited from March 15, 2023. Mr. Zeng was Chairman of Sichuan Hebang Biotechnology Corporation Limited from May 24, 2017. Mr....

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiaoping Zeng	Chairman & GM	8.5yrs	CN¥2.62m	Veri yok
Jun Wang	CFO & Director	16.8yrs	CN¥1.67m	0.037% CN¥ 6.4m
Changhua Yuan	Independent Director	4.5yrs	Veri yok	Veri yok
Zhenggang He	Director	16.8yrs	CN¥2.62m	5.14% CN¥ 903.7m
Changhua Yuan	Independent Director	4.5yrs	CN¥200.00k	Veri yok
Xueling Qin	Director	3.5yrs	CN¥200.00k	0.000050% CN¥ 8.8k
Yang Hu	Independent Director	4.5yrs	CN¥200.00k	Veri yok
Rongpeng Gong	Employee Representative Supervisor	7.5yrs	Veri yok	Veri yok
Tian Chen	Director	1.5yrs	CN¥1.10m	Veri yok
Jing Chen	Chairman of the Supervisory Board	no data	Veri yok	Veri yok
Ying Song	Independent Director	1.5yrs	CN¥200.00k	Veri yok
Jin Li	Director	1.5yrs	CN¥707.80k	Veri yok

4.5yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 603077 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

Sichuan Hebang Biotechnology Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sichuan Hebang Biotechnology Corporation Limited, Annual General Meeting, May 15, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 200 million worth of its shares.

Third quarter 2024 earnings released: EPS: CN¥0.004 (vs CN¥0.046 in 3Q 2023)

Investor sentiment improves as stock rises 25%

Sichuan Hebang Biotechnology Corporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: CN¥0.019 (vs CN¥0.025 in 2Q 2023)

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 200 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited to Report First Half, 2024 Results on Aug 30, 2024

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 200 million worth of its shares.

Investor sentiment deteriorates as stock falls 18%

Sichuan Hebang Biotechnology Corporation Limited, Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.004 (vs CN¥0.046 in 1Q 2023)

Sichuan Hebang Biotechnology Corporation Limited to Report Q1, 2024 Results on Apr 27, 2024

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.046 (vs CN¥0.092 in 3Q 2022)

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

New minor risk - Profit margin trend

Sichuan Hebang Biotechnology Corporation Limited to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.046 (vs CN¥0.12 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.36 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.092 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.078 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.03 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.078 (vs CN¥0.009 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.004 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.005 (vs CN¥0.06 in FY 2019)

New 90-day high: CN¥1.57

New 90-day low: CN¥1.32

New 90-day low: CN¥1.33

New 90-day high: CN¥1.52

New 90-day low: CN¥1.34

Third quarter earnings released

SichuanHebang Biotechnology Co.,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high - CN¥1.63

First half earnings released

New 90-day high - CN¥1.48

SichuanHebang Biotechnology Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş